Listed

Oruka Therapeutics, Inc.

ORKANasdaqCIK 907654HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2025
Operating income−$50.1m, Q2 FY2026
Net income−$41.2m, Q2 FY2026
Oruka Therapeutics, Inc., income statement, quarterly
Line itemUnitQ2 FY20232023-06-30Q3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20252024-03-31Q2 FY20252024-06-30Q3 FY20252024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, Q2 FY2023, three months to 2023-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2023-07-21, accession 0000950170-23-033834. Derived: 6-month figure less the 3-month figure.Report this figure0.0Revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2023-10-18, accession 0000950170-23-053972. Derived: 9-month figure less the 6-month figure.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2024-02-01, accession 0000950170-24-009809. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2024-03-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure0.0Revenue, Q2 FY2025, three months to 2024-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2024-08-01, accession 0000950170-24-089246. Derived: 6-month figure less the 3-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m0.3Research and development, Q1 FY2023, three months to 2023-06-30$254.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure0.3Research and development, Q3 FY2023, three months to 2023-09-30$322.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2023-10-18, accession 0000950170-23-053972.Report this figure0.0Research and development, Q4 FY2023, three months to 2023-12-31$47.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2024-02-01, accession 0000950170-24-009809. Derived: 12-month figure less the 9-month figure.Report this figure0.2Research and development, Q1 FY2025, three months to 2024-03-31$165.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure18.7Research and development, Q2 FY2025, three months to 2024-06-30$18.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure25.7Research and development, Q3 FY2025, three months to 2024-09-30$25.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure19.9Research and development, Q1 FY2025, three months to 2025-03-31$19.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure24.1Research and development, Q2 FY2025, three months to 2025-06-30$24.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure29.0Research and development, Q3 FY2025, three months to 2025-09-30$29.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure27.6Research and development, Q4 FY2025, three months to 2025-12-31$27.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001213900-26-026929. Derived: 12-month figure less the 9-month figure.Report this figure29.1Research and development, Q1 FY2026, three months to 2026-03-31$29.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure43.3Research and development, Q2 FY2026, three months to 2026-06-30$43.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure
Selling, general and administrative$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Operating income$m(2.0)Operating income, Q1 FY2023, three months to 2023-06-30−$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure(1.9)Operating income, Q3 FY2023, three months to 2023-09-30−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2023-10-18, accession 0000950170-23-053972.Report this figure(1.6)Operating income, Q4 FY2023, three months to 2023-12-31−$1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-01, accession 0000950170-24-009809. Derived: 12-month figure less the 9-month figure.Report this figure(2.5)Operating income, Q1 FY2025, three months to 2024-03-31−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure(21.5)Operating income, Q2 FY2025, three months to 2024-06-30−$21.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure(29.4)Operating income, Q3 FY2025, three months to 2024-09-30−$29.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure(25.1)Operating income, Q1 FY2025, three months to 2025-03-31−$25.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure(28.4)Operating income, Q2 FY2025, three months to 2025-06-30−$28.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure(34.1)Operating income, Q3 FY2025, three months to 2025-09-30−$34.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure(34.4)Operating income, Q4 FY2025, three months to 2025-12-31−$34.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001213900-26-026929. Derived: 12-month figure less the 9-month figure.Report this figure(36.4)Operating income, Q1 FY2026, three months to 2026-03-31−$36.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure(50.1)Operating income, Q2 FY2026, three months to 2026-06-30−$50.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure
Interest expense$mnot reportednot reportednot reportednot reported0.8Interest expense, Q2 FY2025, three months to 2024-06-30$750.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure0.5Interest expense, Q3 FY2025, three months to 2024-09-30$504.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(1.5)Net income, Q1 FY2023, three months to 2023-06-30−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure(1.4)Net income, Q3 FY2023, three months to 2023-09-30−$1.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure(1.1)Net income, Q4 FY2023, three months to 2023-12-31−$1.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure(2.0)Net income, Q1 FY2025, three months to 2024-03-31−$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure(22.2)Net income, Q2 FY2025, three months to 2024-06-30−$22.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure(28.6)Net income, Q3 FY2025, three months to 2024-09-30−$28.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure(21.0)Net income, Q1 FY2025, three months to 2025-03-31−$21.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure(24.6)Net income, Q2 FY2025, three months to 2025-06-30−$24.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure(30.3)Net income, Q3 FY2025, three months to 2025-09-30−$30.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure(29.6)Net income, Q4 FY2025, three months to 2025-12-31−$29.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001213900-26-026929. Derived: 12-month figure less the 9-month figure.Report this figure(31.8)Net income, Q1 FY2026, three months to 2026-03-31−$31.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure(41.2)Net income, Q2 FY2026, three months to 2026-06-30−$41.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure
Diluted EPS$ per share(0.10)Diluted EPS, Q1 FY2023, three months to 2023-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure(0.10)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-10-18, accession 0000950170-23-053972.Report this figurenot reported(0.14)Diluted EPS, Q1 FY2025, three months to 2024-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure(6.96)Diluted EPS, Q2 FY2025, three months to 2024-06-30−$6.96 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure(1.46)Diluted EPS, Q3 FY2025, three months to 2024-09-30−$1.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001213900-24-097443.Report this figure(0.40)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-14, accession 0001213900-25-043279.Report this figure(0.46)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figurenot reportednot reportednot reportednot reported
Basic EPS$ per share(0.10)Basic EPS, Q1 FY2023, three months to 2023-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure(0.10)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2023-10-18, accession 0000950170-23-053972.Report this figurenot reported(0.14)Basic EPS, Q1 FY2025, three months to 2024-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure(6.96)Basic EPS, Q2 FY2025, three months to 2024-06-30−$6.96 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure(1.46)Basic EPS, Q3 FY2025, three months to 2024-09-30−$1.46 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001213900-24-097443.Report this figure(0.40)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.40 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-14, accession 0001213900-25-043279.Report this figure(0.46)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.46 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figurenot reportednot reportednot reportednot reported

Balance sheet

Cash and equivalents$268.5m, Q2 FY2026
Shareholders' equity$1.11bn, Q2 FY2026
Oruka Therapeutics, Inc., balance sheet, quarterly
Line itemUnitFY20232023-12-31period not labelled2024-02-06Q1 FY20252024-03-31Q2 FY20252024-06-30Q3 FY20252024-09-30FY20252024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m37.4Cash and equivalents, FY2023, at 2023-12-31$37.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figurenot reported35.9Cash and equivalents, Q1 FY2025, at 2024-03-31$35.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure33.3Cash and equivalents, Q2 FY2025, at 2024-06-30$33.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure411Cash and equivalents, Q3 FY2025, at 2024-09-30$410.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0001213900-24-097443.Report this figure61.6Cash and equivalents, FY2025, at 2024-12-31$61.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-12, accession 0001213900-26-026929.Report this figure83.6Cash and equivalents, Q1 FY2025, at 2025-03-31$83.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-14, accession 0001213900-25-043279.Report this figure65.4Cash and equivalents, Q2 FY2025, at 2025-06-30$65.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure91.3Cash and equivalents, Q3 FY2025, at 2025-09-30$91.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure46.9Cash and equivalents, FY2025, at 2025-12-31$46.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure49.5Cash and equivalents, Q1 FY2026, at 2026-03-31$49.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure268Cash and equivalents, Q2 FY2026, at 2026-06-30$268.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure
Current assets$m37.6Current assets, FY2023, at 2023-12-31$37.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure0.0Current assets, period not labelled, at 2024-02-06$1.0k. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-06, accession 0001213900-25-021165.Report this figure36.7Current assets, Q1 FY2025, at 2024-03-31$36.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure33.8Current assets, Q2 FY2025, at 2024-06-30$33.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure413Current assets, Q3 FY2025, at 2024-09-30$412.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001213900-24-097443.Report this figure377Current assets, FY2025, at 2024-12-31$376.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-12, accession 0001213900-26-026929.Report this figure352Current assets, Q1 FY2025, at 2025-03-31$352.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-14, accession 0001213900-25-043279.Report this figure332Current assets, Q2 FY2025, at 2025-06-30$332.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure355Current assets, Q3 FY2025, at 2025-09-30$355.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure344Current assets, FY2025, at 2025-12-31$343.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure395Current assets, Q1 FY2026, at 2026-03-31$395.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure885Current assets, Q2 FY2026, at 2026-06-30$884.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure
Total assets$m37.9Total assets, FY2023, at 2023-12-31$37.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure0.0Total assets, period not labelled, at 2024-02-06$1.0k. XBRL concept us-gaap:Assets. 10-K filed 2025-03-06, accession 0001213900-25-021165.Report this figure36.7Total assets, Q1 FY2025, at 2024-03-31$36.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure33.8Total assets, Q2 FY2025, at 2024-06-30$33.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure414Total assets, Q3 FY2025, at 2024-09-30$414.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001213900-24-097443.Report this figure396Total assets, FY2025, at 2024-12-31$396.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-12, accession 0001213900-26-026929.Report this figure377Total assets, Q1 FY2025, at 2025-03-31$377.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-14, accession 0001213900-25-043279.Report this figure357Total assets, Q2 FY2025, at 2025-06-30$357.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure509Total assets, Q3 FY2025, at 2025-09-30$509.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure489Total assets, FY2025, at 2025-12-31$488.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure504Total assets, Q1 FY2026, at 2026-03-31$504.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure1,139Total assets, Q2 FY2026, at 2026-06-30$1.14bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure
Current liabilities$m0.6Current liabilities, FY2023, at 2023-12-31$637.0k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figurenot reported1.6Current liabilities, Q1 FY2025, at 2024-03-31$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure1.3Current liabilities, Q2 FY2025, at 2024-06-30$1.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure18.0Current liabilities, Q3 FY2025, at 2024-09-30$18.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001213900-24-097443.Report this figure13.0Current liabilities, FY2025, at 2024-12-31$13.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-12, accession 0001213900-26-026929.Report this figure11.7Current liabilities, Q1 FY2025, at 2025-03-31$11.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-14, accession 0001213900-25-043279.Report this figure12.1Current liabilities, Q2 FY2025, at 2025-06-30$12.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure21.0Current liabilities, Q3 FY2025, at 2025-09-30$21.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure15.4Current liabilities, FY2025, at 2025-12-31$15.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure16.6Current liabilities, Q1 FY2026, at 2026-03-31$16.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure23.0Current liabilities, Q2 FY2026, at 2026-06-30$23.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure
Total liabilities$m0.8Total liabilities, FY2023, at 2023-12-31$841.0k. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figurenot reported1.6Total liabilities, Q1 FY2025, at 2024-03-31$1.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure1.3Total liabilities, Q2 FY2025, at 2024-06-30$1.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure18.9Total liabilities, Q3 FY2025, at 2024-09-30$18.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001213900-24-097443.Report this figure13.8Total liabilities, FY2025, at 2024-12-31$13.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-12, accession 0001213900-26-026929.Report this figure12.4Total liabilities, Q1 FY2025, at 2025-03-31$12.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-14, accession 0001213900-25-043279.Report this figure13.8Total liabilities, Q2 FY2025, at 2025-06-30$13.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure22.5Total liabilities, Q3 FY2025, at 2025-09-30$22.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure16.7Total liabilities, FY2025, at 2025-12-31$16.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure17.8Total liabilities, Q1 FY2026, at 2026-03-31$17.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure24.8Total liabilities, Q2 FY2026, at 2026-06-30$24.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure
Shareholders' equity$m37.0Shareholders' equity, FY2023, at 2023-12-31$37.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure0.0Shareholders' equity, period not labelled, at 2024-02-05$1.0k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-14, accession 0001213900-25-043279.Report this figure(7.1)Shareholders' equity, Q1 FY2025, at 2024-03-31−$7.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure(29.0)Shareholders' equity, Q2 FY2025, at 2024-06-30−$29.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure342Shareholders' equity, Q3 FY2025, at 2024-09-30$342.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure382Shareholders' equity, FY2025, at 2024-12-31$382.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure365Shareholders' equity, Q1 FY2025, at 2025-03-31$364.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure344Shareholders' equity, Q2 FY2025, at 2025-06-30$343.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure487Shareholders' equity, Q3 FY2025, at 2025-09-30$486.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001213900-25-109182.Report this figure472Shareholders' equity, FY2025, at 2025-12-31$471.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure487Shareholders' equity, Q1 FY2026, at 2026-03-31$486.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure1,115Shareholders' equity, Q2 FY2026, at 2026-06-30$1.11bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure

Cash flow

Operating cash flow−$33.1m, Q2 FY2026
Capital expenditure$0, Q2 FY2026
Oruka Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20252024-03-31Q2 FY20252024-06-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(1.6)Operating cash flow, Q1 FY2023, three months to 2023-03-31−$1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure(0.7)Operating cash flow, Q2 FY2023, three months to 2023-06-30−$694.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-08-01, accession 0000950170-24-089246. Derived: 6-month figure less the 3-month figure.Report this figure(1.7)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-10-18, accession 0000950170-23-053972. Derived: 9-month figure less the 6-month figure.Report this figure(1.1)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-01, accession 0000950170-24-009809. Derived: 12-month figure less the 9-month figure.Report this figure(1.5)Operating cash flow, Q1 FY2025, three months to 2024-03-31−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure(2.6)Operating cash flow, Q2 FY2025, three months to 2024-06-30−$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-08-01, accession 0000950170-24-089246. Derived: 6-month figure less the 3-month figure.Report this figure(20.9)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$20.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure(23.1)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$23.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001213900-26-087231. Derived: 6-month figure less the 3-month figure.Report this figure(21.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$21.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001213900-25-109182. Derived: 9-month figure less the 6-month figure.Report this figure(22.6)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$22.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001213900-26-026929. Derived: 12-month figure less the 9-month figure.Report this figure(23.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$23.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure(33.1)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$33.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001213900-26-087231. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$mnot reportednot reportednot reportednot reportednot reportednot reported0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$13.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$34.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001213900-26-087231. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$99.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001213900-25-109182. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$63.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001213900-26-026929. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$73.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001213900-26-055769.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001213900-26-087231. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)42.10m, Q2 FY2025
Oruka Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20212021-09-30Q1 FY20222022-03-31Q2 FY20222022-06-30Q3 FY20222022-09-30Q1 FY20232023-03-31Q1 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20252024-03-31Q2 FY20252024-06-30Q3 FY20252024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30
Diluted shares (weighted)m shares14.4Diluted shares (weighted), Q3 FY2021, three months to 2021-09-3014,410,143 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-10-28, accession 0001564590-22-035668.Report this figure14.4Diluted shares (weighted), Q1 FY2022, three months to 2022-03-3114,410,143 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-04-24, accession 0000950170-23-014091.Report this figure14.4Diluted shares (weighted), Q2 FY2022, three months to 2022-06-3014,410,143 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-07-21, accession 0000950170-23-033834.Report this figure14.4Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3014,410,143 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-10-18, accession 0000950170-23-053972.Report this figure14.4Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3114,410,143 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure14.4Diluted shares (weighted), Q1 FY2023, three months to 2023-06-3014,410,143 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-01, accession 0000950170-24-089246.Report this figure14.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3014,410,143 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-10-18, accession 0000950170-23-053972.Report this figure14.5Diluted shares (weighted), Q1 FY2025, three months to 2024-03-3114,501,143 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-04-25, accession 0000950170-24-048329.Report this figure3.2Diluted shares (weighted), Q2 FY2025, three months to 2024-06-303,197,975 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure15.0Diluted shares (weighted), Q3 FY2025, three months to 2024-09-3015,013,655 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001213900-24-097443.Report this figure41.7Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3141,679,560 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-14, accession 0001213900-25-043279.Report this figure42.1Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3042,095,951 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0001213900-25-074281.Report this figure

Shares outstanding: 66.21mShares outstanding, period not labelled, at 2026-07-3166,209,699 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-10, accession 0001213900-26-087231.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. Listed shows no prices and gives no investment advice.